JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Recursion Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

5.54 -4.15

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.41

Max

5.94

Galvenie mērījumi

By Trading Economics

Ienākumi

-24M

-202M

Pārdošana

10M

15M

Peļņas marža

-1,373.259

Darbinieki

800

EBITDA

-26M

-191M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+7.76% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

419M

2.7B

Iepriekšējā atvēršanas cena

9.69

Iepriekšējā slēgšanas cena

5.54

Ziņu noskaņojums

By Acuity

50%

50%

176 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. aug. 23:11 UTC

Peļņas

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

2025. g. 5. aug. 22:45 UTC

Peļņas

Australia's REA Hikes Dividend as Annual Profit Rises 23%

2025. g. 5. aug. 22:39 UTC

Peļņas

Great-West Lifeco Logs Lower 2Q Profit

2025. g. 5. aug. 21:32 UTC

Peļņas

Coupang Posts Higher 2Q Sales Due to Customer Growth

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

NFL to Take 10% Stake in Disney's ESPN -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

2025. g. 5. aug. 23:48 UTC

Tirgus saruna

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

2025. g. 5. aug. 23:40 UTC

Tirgus saruna

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

2025. g. 5. aug. 23:19 UTC

Tirgus saruna

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

2025. g. 5. aug. 23:03 UTC

Tirgus saruna
Peļņas

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

2025. g. 5. aug. 22:22 UTC

Peļņas

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

2025. g. 5. aug. 22:21 UTC

Peļņas

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

2025. g. 5. aug. 22:20 UTC

Peļņas

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

2025. g. 5. aug. 22:18 UTC

Peļņas

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

2025. g. 5. aug. 22:17 UTC

Peļņas

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

2025. g. 5. aug. 22:17 UTC

Peļņas

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

2025. g. 5. aug. 22:16 UTC

Peļņas

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

2025. g. 5. aug. 22:16 UTC

Peļņas

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

2025. g. 5. aug. 22:15 UTC

Peļņas

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

2025. g. 5. aug. 22:13 UTC

Peļņas

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

2025. g. 5. aug. 22:13 UTC

Peļņas

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

2025. g. 5. aug. 22:12 UTC

Peļņas

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

2025. g. 5. aug. 22:12 UTC

Peļņas

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

2025. g. 5. aug. 21:58 UTC

Peļņas

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

2025. g. 5. aug. 21:30 UTC

Peļņas

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

2025. g. 5. aug. 21:26 UTC

Peļņas

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

2025. g. 5. aug. 21:23 UTC

Peļņas

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

2025. g. 5. aug. 21:17 UTC

Peļņas

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Salīdzinājums

Cenas izmaiņa

Recursion Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

7.76% augšup

Prognoze 12 mēnešiem

Vidējais 6.25 USD  7.76%

Augstākais 8 USD

Zemākais 4 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Recursion Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

5 ratings

1

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

4.15 / 4.75Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

176 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.